Idera News
Most Popular Idera Story
Idera's cancer drug disappoints in Phase II
Cambridge, MA-based Idera Pharmaceuticals is reporting disappointing preliminary results from a Phase II trial of IMO-2055. The primary endpoint--tumor response based on RECIST (response evaluation... Read more...
Latest Headlines
- October 1, 2008
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
